🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

3 recruiting trials

for Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) NCT03328078Phase 1, Phase 245 sites📍 Phoenix📍 Phoenix📍 Duarte Curis, Inc. · Tests: Emavusertib, Ibrutinib The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients. NCT05931328Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: thiotepa combined with pomalidomide NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL NCT06737250Phase 210 sites📍 Busan📍 Hwasun📍 Ilsan NOBO Medicine · Tests: R2P -> RP
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy